Startups
Astellas Pharma
Astellas Pharma Inc. is a Tokyo-based global life sciences company listed on the Tokyo Stock Exchange (4503). It develops and commercializes therapies in oncology, ophthalmology, urology, immunology and women’s health, and advances drug discovery through genetic regulation, regenerative medicine and other biological platforms. Its Astellas Gene Therapies center develops AAV genetic medicines for rare diseases affecting the eye, central nervous system and neuromuscular system. The company also pursues digital and technology-enabled healthcare through its Rx+ activities. In October2024, Astellas Pharma committed a USD20million equity investment in neurodegenerative gene therapy developer AviadoBio alongside a separate option and license agreement for investigational AVB-101. The operating pharmaceutical company is the named investor in that agreement.
Team
 Atsushi KitamuraChief Financial Officer (CFO) |
 Claus ZielerChief Commercial & Medical Affairs Officer (CCMAO) |
 Katsuyoshi SugitaRepresentative Director, Executive Vice President, Chief People Officer (CPO) |
 Kenji YasukawaRepresentative Director, Chairman of the Board |
 Mark EnyedyOutside Director |
 Masahiro MiyazakiOutside Director |
 Nahrin MarinoGeneral Counsel and Chief Ethics & Compliance Officer (GC & CECO) |
 Naoki OkamuraRepresentative Director, President and Chief Executive Officer (CEO) |
 Rao MantriChief Manufacturing Officer (CMfgO) |
 Rie AkiyamaOutside Director, Audit & Supervisory Committee Member |
 Rika HirotaDirector, Audit & Supervisory Committee Member |
 Shigeki TakaharaOutside Director, Audit & Supervisory Committee Member |
 Tadaaki TaniguchiChief Research & Development Officer (CRDO) |
 Takahiko IwayaChief Strategy Officer (CStO) |
 Tomoko AramakiOutside Director, Audit & Supervisory Committee Member |
 Yoichi OhnoOutside Director |
Investments
| $20M2024-10-08 |  AviadoBio | Astellas Pharma |